Deferoxamine mesylate inj
Products billed under this code include Deferoxamine Mesylate, Desferal.
Payment limit per 500 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Deferoxamine Mesylate, Desferal.
Payment limit per 500 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Deferoxamine Mesylate | Pfizer Inc | 00409-2337-25 | 16 | $140.432 |
| Deferoxamine Mesylate | Apotex Corp | 60505-6236-06 | 4 | $35.108 |
| Deferoxamine Mesylate | Apotex Corp | 60505-6238-06 | 4 | $35.108 |
| Deferoxamine Mesylate | FreseniUS Kabi USA, LLC | 63323-0597-10 | 1 | $8.777 |
| Deferoxamine Mesylate | FreseniUS Kabi USA, LLC | 63323-0599-30 | 4 | $35.108 |
| Desferal | Novartis Pharmaceuticals Corporation | 00078-0467-91 | 4 | $35.108 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $8.777 | −$1.243 | 500 MG | Deferoxamine mesylate inj | v1, posted September 17, 2026 |
| 3Q26 | $10.02 | +$1.443 | 500 MG | Deferoxamine mesylate inj | v1, posted September 15, 2026 |
| 2Q26 | $8.577 | +$0.109 | 500 MG | Deferoxamine mesylate inj | v1, posted September 15, 2026 |
| 1Q26 | $8.468 | −$0.541 | 500 MG | Deferoxamine mesylate inj | v1, posted September 15, 2026 |
| 4Q25 | $9.009 | −$0.007 | 500 MG | Deferoxamine mesylate inj | v1, posted September 8, 2026 |
| 3Q25 | $9.016 | +$0.808 | 500 MG | Deferoxamine mesylate inj | v1, posted March 10, 2026 |
| 2Q25 | $8.208 | −$0.729 | 500 MG | Deferoxamine mesylate inj | v1, posted March 10, 2026 |
| 1Q25 | $8.937 | +$2.159 | 500 MG | Deferoxamine mesylate inj | v1, posted December 19, 2025 |
| 4Q24 | $6.778 | −$0.122 | 500 MG | Deferoxamine mesylate inj | v1, posted June 11, 2025 |
| 3Q24 | $6.90 | −$2.121 | 500 MG | Deferoxamine mesylate inj | v1, posted June 11, 2025 |
| 2Q24 | $9.021 | +$0.424 | 500 MG | Deferoxamine mesylate inj | v1, posted March 11, 2025 |
| 1Q24 | $8.597 | +$0.006 | 500 MG | Deferoxamine mesylate inj | v1, posted December 19, 2024 |
| 4Q23 | $8.591 | −$0.001 | 500 MG | Deferoxamine mesylate inj | v1, posted October 10, 2024 |
| 3Q23 | $8.592 | +$0.377 | 500 MG | Deferoxamine mesylate inj | v1, posted June 5, 2024 |
| 2Q23 | $8.215 | −$0.448 | 500 MG | Deferoxamine mesylate inj | v1, posted February 23, 2024 |
| 1Q23 | $8.663 | +$0.735 | 500 MG | Deferoxamine mesylate inj | v1, posted December 6, 2023 |
| 4Q22 | $7.928 | −$2.488 | 500 MG | Deferoxamine mesylate inj | v1, posted June 22, 2023 |
| 3Q22 | $10.416 | +$3.218 | 500 MG | Deferoxamine mesylate inj | v1, posted June 9, 2023 |
| 2Q22 | $7.198 | −$0.668 | 500 MG | Deferoxamine mesylate inj | v1, posted December 14, 2022 |
| 1Q22 | $7.866 | +$0.204 | 500 MG | Deferoxamine mesylate inj | v1, posted June 8, 2022 |
| 4Q21 | $7.662 | −$0.935 | 500 MG | Deferoxamine mesylate inj | v1, posted June 2, 2022 |
| 3Q21 | $8.597 | −$0.03 | 500 MG | Deferoxamine mesylate inj | v1, posted June 2, 2022 |
| 2Q21 | $8.627 | +$0.726 | 500 MG | Deferoxamine mesylate inj | v1, posted March 1, 2022 |
| 1Q21 | $7.901 | – | 500 MG | Deferoxamine mesylate inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.